PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy and hospital pharmacy management services, today reported the results of its first quarter ended March 31, 2010.
Commenting on the Company’s results for the quarter, Gregory S. Weishar, PharMerica Corporation’s Chief Executive Officer, said, “We performed reasonably well, achieving a modest increase in net income and executing our plan for the first quarter. Though EBITDA decreased from last year, cash flow from operations showed significant improvement, bolstered by new prompt pay legislation. While we will continue to face margin headwinds for the remainder of the year, we are maintaining our 2010 guidance as we anticipate operating improvements over the last half of the year as our initiatives bear fruit.”
- Key Comparisons of First Quarters Ended March 31, 2010 and 2009:
- Net income increased to $8.4 million, or $0.27 earnings per diluted share, compared with net income of $8.2 million, or $0.27 earnings per diluted share.
- Cash Flow Provided by Operating Activities increased 77.7% to $24.7 million from $13.9 million.
- Adjusted EBITDA decreased 8.3% to $23.1 million from $25.2 million.
- The Company maintains its previous earnings guidance for 2010.
Conference Call
Management will hold a conference call to review the financial results for the first quarter ended March 31, 2010, on May 7, 2010, at 10:00 a.m. ET. To access the live webcast, visit the Investor Relations section of the Company’s website at www.pharmerica.com or go to www.earnings.com. To access a telephonic replay of the call, which will be available one hour after the conclusion of the call through May 21, 2010, please dial 1-888-286-8010 (617-801-6888 if calling from outside the U.S.) and use passcode 69803149.
About PharMerica
PharMerica Corporation is a leading institutional pharmacy services company servicing healthcare facilities in the United States. As of March 31, 2010, PharMerica operated 91 institutional pharmacies in 41 states. PharMerica’s customers are institutional healthcare providers, such as nursing centers, assisted living facilities, hospitals and other long-term care providers. The Company also provides pharmacy management services to long-term care hospitals.
Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which reflect the Company’s current estimates, expectations and projections about its future results, performance, prospects and opportunities. Forward-looking statements include, among other matters, the information concerning the Company’s “guidance” and possible future results of operations, the Company’s ability to purchase acquisition targets, the accretive affect of completed acquisitions on the Company’s operating results and financial position, the continued strength of the Company’s cash flows from operations, the Company’s review of its cost structure and the strength of the Company’s financial performance during 2010. Forward-looking statements include statements that are not historical facts and can be identified by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “plan,” “may,” “should,” “will,” “would,” “project” and similar expressions. These forward-looking statements are based upon information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause the Company’s actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. Important factors that could cause the Company’s actual results to differ materially from the results referred to in the forward-looking statements we make in this press release are included in the Risk Factors section set forth in the Company’s Annual Report on Form 10-K filed with the SEC and in other reports, including current reports on Form 10-Q, filed with the SEC by the Company.
You are cautioned not to place undue reliance on any forward-looking statements, all of which speak only as of the date of this press release.Except as required by law, we undertake no obligation to publicly update or release any revisions to these forward-looking statements to reflect any events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events. All subsequent written and oral forward-looking statements attributable to us or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this press release and in the Risk Factors section set forth in the Company’s Annual Report on Form 10-K filed with the SEC and in other reports filed with the SEC by the Company.
PHARMERICA CORPORATION UNAUDITED CONDENSED CONSOLIDATED INCOME STATEMENTS (In millions, except share and per share amounts) | ||||||||||||
| Quarter Ended March 31, | ||||||||||||
| 2009 | 2010 | |||||||||||
| Amount | % of Revenues | Amount | % of Revenues | |||||||||
| Revenues | $ | 468.2 | 100.0 | % | $ | 462.2 | 100.0 | % | ||||
| Cost of goods sold | 396.8 | 84.7 | 399.5 | 86.4 | ||||||||
| Gross profit | 71.4 | 15.3 | 62.7 | 13.6 | ||||||||
| Selling, general and administrative expenses | 50.9 | 10.9 | 44.2 | 9.6 | ||||||||
| Amortization expense | 1.8 | 0.4 | 2.3 | 0.5 | ||||||||
Integration, merger and acquisition related costs and other charges | 2.0 | 0.4 | 1.2 | 0.3 | ||||||||
| Operating income | 16.7 | 3.6 | 15.0 | 3.2 | ||||||||
| Interest expense, net | 3.2 | 0.7 | 0.9 | 0.2 | ||||||||
| Income before income taxes | 13.5 | 2.9 | 14.1 | 3.0 | ||||||||
| Provision for income taxes | 5.3 | 1.1 | 5.7 | 1.2 | ||||||||
| Net income | $ | 8.2 | 1.8 | % | $ | 8.4 | 1.8 | % | ||||
| Quarter Ended March 31, | ||||||
| 2009 | 2010 | |||||
| Earnings per common share: | ||||||
| Basic | $ | 0.27 | $ | 0.28 | ||
| Diluted | $ | 0.27 | $ | 0.27 | ||
| Shares used in computing earnings per common share: | ||||||
| Basic | 30,211,699 | 30,396,520 | ||||
| Diluted | 30,311,930 | 30,571,049 | ||||
PHARMERICA CORPORATION UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In millions, except share and per share amounts) | ||||||
| Dec. 31, 2009 | March 31, 2010 | |||||
| ASSETS | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 51.2 | $ | 73.5 | ||
| Accounts receivable, net | 215.3 | 204.2 | ||||
| Inventory | 79.8 | 77.1 | ||||
| Deferred tax assets | 39.8 | 41.4 | ||||
| Prepaids and other assets | 23.6 | 19.8 | ||||
| 409.7 | 416.0 | |||||
| Equipment and leasehold improvements | 119.6 | 122.0 | ||||
| Accumulated depreciation | (59.0 | ) | (63.5 | ) | ||
| 60.6 | 58.5 | |||||
| Deferred tax assets, net | 21.0 | 14.6 | ||||
| Goodwill | 140.1 | 140.6 | ||||
| Intangible assets, net | 90.8 | 88.8 | ||||
| Other | 2.1 | 1.8 | ||||
| $ | 724.3 | $ | 720.3 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ | 59.6 | $ | 48.5 | ||
| Salaries, wages and other compensation | 30.9 | 29.5 | ||||
| Other accrued liabilities | 6.4 | 6.7 | ||||
| 96.9 | 84.7 | |||||
| Long-term debt | 240.0 | 240.0 | ||||
| Other long-term liabilities | 16.5 | 15.4 | ||||
| Commitments and contingencies | ||||||
| Stockholders’ equity: | ||||||
Preferred stock, $0.01 par value per share; 1,000,000 shares authorized and no shares issued at December 31, 2009 and March 31, 2010 | – | – | ||||
| Common stock, $0.01 par value per share; 175,000,000 shares authorized; 30,619,830 shares and 30,632,218 shares issued and outstanding as of December 31, 2009 and March 31, 2010, respectively | 0.3 | 0.3 | ||||
| Capital in excess of par value | 344.8 | 345.7 | ||||
| Retained earnings | 25.8 | 34.2 | ||||
| 370.9 | 380.2 | |||||
| $ | 724.3 | $ | 720.3 | |||
PHARMERICA CORPORATION UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In millions) | ||||
| Quarter Ended March 31, | ||||
| 2009 | 2010 | |||
| Cash flows provided by operating activities: | ||||
| Net income | $ 8.2 | $ 8.4 | ||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation | 4.7 | 4.6 | ||
| Amortization | 1.8 | 2.3 | ||
| Integration, merger and acquisition related costs and other charges | 0.2 | 0.1 | ||
| Stock-based compensation | 0.6 | 0.8 | ||
| Amortization of deferred financing fees | 0.1 | 0.2 | ||
| Deferred income taxes | 4.8 | 4.8 | ||
| Loss on disposition of equipment | 0.1 | – | ||
| Other | (0.1) | 0.1 | ||
| Change in operating assets and liabilities: | ||||
| Accounts receivable, net | 0.6 | 11.1 | ||
| Inventory and other assets | 1.4 | 2.6 | ||
| Prepaids and other assets | 3.1 | 3.8 | ||
| Accounts payable | (8.0) | (11.5) | ||
| Salaries, wages and other compensation | (5.0) | (2.8) | ||
| Other accrued liabilities | 1.4 | 0.2 | ||
| Net cash provided by operating activities | 13.9 | 24.7 | ||
| Cash flows used in investing activities: | ||||
| Purchase of equipment and leasehold improvements | (3.2) | (2.2) | ||
| Other | – | (0.1) | ||
| Net cash used in investing activities | (3.2) | (2.3) | ||
| Cash flows provided by (used in) financing activities: | ||||
| Repayments of capital lease obligations | (0.1) | (0.2) | ||
| Issuance of common stock | 0.1 | 0.1 | ||
| Tax benefit from stock-based compensation | 0.1 | – | ||
| Net cash provided by (used in) financing activities | 0.1 | (0.1) | ||
| Change in cash and cash equivalents | 10.8 | 22.3 | ||
| Cash and cash equivalents at beginning of period | 41.3 | 51.2 | ||
| Cash and cash equivalents at end of period | $ 52.1 | $ 73.5 | ||
| Supplemental information: | ||||
| Cash paid for interest | $ 3.3 | $ 0.8 | ||
| Cash paid (refund) for taxes | $ 0.3 | $ (0.2) | ||
| Supplemental schedule of non-cash activities: | ||||
| Capital lease obligations | $ 1.8 | $ 0.4 | ||
| Integrity working capital adjustment | $ – | $ 0.5 | ||
PHARMERICA CORPORATION
SUPPLEMENTAL INFORMATION
INTEGRATION, MERGER AND ACQUISITION RELATED COSTS AND OTHER CHARGES
The following is a summary of integration, merger and acquisition related costs and other charges incurred by PharMerica in the first quarters of 2009 and 2010 (unaudited).
| (In millions, except per share amounts) | Quarter Ended March 31, | |||
| 2009 | 2010 | |||
| Integration costs and other charges: | ||||
| Professional and advisory fees | $ – | $ 0.2 | ||
| General and administrative | 0.2 | 0.2 | ||
| Employee costs | 0.8 | 0.1 | ||
| Severance costs | 0.4 | 0.1 | ||
| Facility costs | 0.6 | – | ||
| 2.0 | 0.6 | |||
| Acquisition related costs: | ||||
| Professional and advisory fees | – | 0.2 | ||
| General and administrative | – | 0.4 | ||
| – | 0.6 | |||
| Total integration, merger and acquisition related costs and other charges | $ 2.0 | $ 1.2 | ||
Negative effect on earnings per diluted share | $ (0.04) | $ (0.02) | ||
CUSTOMER LICENSED BEDS UNDER CONTRACT AND PRESCRIPTION DATA
The following is a summary of customer licensed beds under contract and prescription data as of and for the first quarters ended 2009 and 2010 (unaudited).
| (In whole numbers, except where indicated) | Quarter Ended March 31, | ||
| 2009 | 2010 | ||
| Customer licensed beds: | |||
| Beginning of period | 322,376 | 317,885 | |
| Additions | 6,762 | 5,126 | |
| Losses | (8,393) | (10,857) | |
| End of period | 320,745 | 312,154 | |
| Prescription data: | |||
| Prescriptions dispensed (in thousands) | 9,919 | 9,664 | |
| Revenue per prescription dispensed | $ 45.71 | $ 46.39 | |
PHARMERICA CORPORATION SUPPLEMENTAL INFORMATION (Continued) UNAUDITED RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA | ||||||
| (In millions) | Quarter Ended March 31, | |||||
| 2009 | 2010 | |||||
| Net income | $ | 8.2 | $ | 8.4 | ||
| Add: | ||||||
| Interest expense, net | 3.2 | 0.9 | ||||
| Integration, merger and acquisition related costs and other charges | 2.0 | 1.2 | ||||
| Provision for income taxes | 5.3 | 5.7 | ||||
| Depreciation and amortization expense | 6.5 | 6.9 | ||||
| Adjusted EBITDA | $ | 25.2 | $ | 23.1 | ||
| Adjusted EBITDA margin | 5.4 | % | 5.0 | % | ||
UNAUDITED RECONCILIATION OF EARNINGS PER DILUTED SHARE TO ADJUSTED EARNINGS PER DILUTED SHARE | |||||
| (In whole numbers) | Quarter Ended March 31, | ||||
| 2009 | 2010 | ||||
| Earnings per diluted common share | $ | 0.27 | $ | 0.27 | |
| Add: Integration, merger and acquisition related costs and other charges | 0.04 | 0.02 | |||
| Adjusted earnings per diluted common share after impact of above items | $ | 0.31 | $ | 0.29 | |
UNAUDITED RECONCILIATION OF ADJUSTED EBITDA TO NET OPERATING CASH FLOWS | ||||||
| (In millions) | Quarter Ended March 31, | |||||
| 2009 | 2010 | |||||
| Adjusted EBITDA | $ | 25.2 | $ | 23.1 | ||
| Interest expense, net | (3.2 | ) | (0.9 | ) | ||
| Provision for income taxes | (5.3 | ) | (5.7 | ) | ||
| Integration, merger and acquisition related costs and other charges | (1.8 | ) | (1.1 | ) | ||
| Provision for bad debt | 7.1 | 3.8 | ||||
| Stock-based compensation | 0.6 | 0.8 | ||||
| Amortization of deferred financing fees | 0.1 | 0.2 | ||||
| Deferred income taxes | 4.8 | 4.8 | ||||
| Loss on disposition of equipment | 0.1 | – | ||||
| Other | (0.1 | ) | 0.1 | |||
| Changes in assets and liabilities | (13.6 | ) | (0.4 | ) | ||
| Net Cash Flows from Operating Activities | $ | 13.9 | $ | 24.7 | ||
Use of Non-GAAP Measures
PharMerica calculates Adjusted EBITDA as provided in the reconciliation above and calculates Adjusted EBITDA Margin by taking Adjusted EBITDA and dividing it by revenues. PharMerica calculates and uses Adjusted EBITDA as an indicator of its ability to generate cash from reported operating results. The measurement is used in concert with net income and cash flows from operations, which measure actual cash generated in the period. In addition, PharMerica believes that Adjusted EBITDA and Adjusted EBITDA Margin are supplemental measurement tools used by analysts and investors to help evaluate overall operating performance and the ability to incur and service debt and make capital expenditures. Adjusted EBITDA, as defined in the Company’s Credit Agreement, is used in conjunction with PharMerica’s debt leverage ratio and this calculation sets the applicable margin for the quarterly interest charge. Adjusted EBITDA, as defined in the Company’s Credit Agreement, is not the same calculation as this Adjusted EBITDA table. Adjusted EBITDA does not represent funds available for PharMerica’s discretionary use and is not intended to represent or to be used as a substitute for net income or cash flows from operations data as measured under U.S. generally accepted accounting principles (“GAAP”). The items excluded from Adjusted EBITDA but included in the calculation of PharMerica’s reported net income are significant components of the accompanying unaudited condensed consolidated income statements and cash flows, and must be considered in performing a comprehensive assessment of overall financial performance. PharMerica’s calculation of Adjusted EBITDA may not be consistent with calculations of EBITDA used by other companies.
PharMerica calculates and uses adjusted earnings per diluted share, exclusive of the impact of integration, merger and acquisition related costs and other charges, as an indicator of its core operating results. The measurement is used in concert with net income and earnings per diluted share, which measure actual earnings per share generated in the period. PharMerica believes the exclusion of these charges in expressing adjusted earnings per share provides management with a useful measure to assess period to period comparability and is useful to investors in evaluating PharMerica’s operating results from period to period. Adjusted earnings per diluted share, exclusive of integration, merger and acquisition related costs and other charges, does not represent the amount that effectively accrues directly to stockholders (i.e., such costs are a reduction in earnings and stockholders’ equity) and is not intended to represent or to be used as a substitute for earnings per diluted share as measured under GAAP. The impact of integration, merger and acquisition related costs and other charges excluded from the earnings per diluted share is a significant component of the accompanying unaudited condensed consolidated income statements, and must be considered in performing a comprehensive assessment of overall financial performance.
Contacts:
Michael J. Culotta, 502-627-7475
Executive
Vice President and Chief Financial Officer
